IFNG and neoplasm: Our study shows that this TCR has therapeutic potential for use in TCR-engineered T cell therapy, but that other therapies that increase IFN-γ signaling in the tumor microenvironment may be required to enhance tumor recognition by the TCR-engineered T cells and increase therapeutic activity.